Where can I buy adagene shares?
Shares of ADAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adagene's stock price today?
What is the upside for adagene's (ADAG) stock?
Their ADAG stock forecasts range from $15.00 to $15.00. On average, they predict Adagene's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 747.5% from the stock's current price. View analysts' price targets for Adagene or view top-rated stocks among Wall Street analysts.
What is adagene's stock price for 2022?
Adagene's stock was trading at $8.0684 on January 1st, 2022. Since then, ADAG stock has decreased by 78.1% and is now trading at $1.77. View the best growth stocks for 2022 here. Who are Adagene's key executives? Ms. Ami Celeste Knoefler, VP of Investor Relations & Corp. Communications Who are some of Adagene's key competitors?
Does adagene Inc (ADAG) have a clinical trial?
Adagene Inc (NASDAQ: ADAG) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes two clinical studies to evaluate Adagene's anti-C... Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (AD...
Should I buy or sell Adagene stock right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last year. There are currently 1 buy rating for th...
What is Adagene's stock price forecast for 2022?
1 analysts have issued 1-year target prices for Adagene's stock. Their forecasts range from $15.00 to $15.00. On average, they anticipate Adagene's...
How has Adagene's stock performed in 2022?
Adagene's stock was trading at $8.0684 at the beginning of 2022. Since then, ADAG stock has decreased by 68.3% and is now trading at $2.56. View t...
Are investors shorting Adagene?
Adagene saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 62,600 shares, a decrease of 18.0%...
Who are Adagene's key executives?
Adagene's management team includes the following people: Dr. Peter P. Luo Ph.D. , Co-Founder, CEO & Chairman (Age 56) Mr. Man Kin Tam M.B.A. ,...
Who are some of Adagene's key competitors?
Some companies that are related to Adagene include Cara Therapeutics (CARA) , 2seventy bio (TSVT) , Stoke Therapeutics (STOK) , IDEAYA Bioscien...
When did Adagene IPO?
(ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per sh...
What is Adagene's stock symbol?
Adagene trades on the NASDAQ under the ticker symbol "ADAG."
Who are Adagene's major shareholders?
Adagene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital International Investo...
What is Adagene Inc?
How much did Adagene make in 2020?
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of variou... [Read more...]
Is Adagene a phase 1 company?
In 2020, Adagene's revenue was $700,913, an increase of 46.02% compared to the previous year's $480,000. Losses were -$42.40 million, 158.0% more than in 2019.
Is Dragonfly a partner of Abbvie?
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tues day with the SEC to raise up to $125 million in an initial public offering. 6 months ago - NASDAQ.
Is Adagene going public?
Dragonfly’s partnership with AbbVie is beginning to bear fruit. AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment, the compa...
Who bought Adag stock?
Adagene, Inc. has filed to go public with an IPO on the NASDAQ.
When does Adagene's lock up expire?
ADAG stock was bought by a variety of institutional investors in the last quarter, including E Fund Management Co. Ltd..
What is the ADAG symbol?
Adagene's lock-up period expires on Monday, August 9th. Adagene had issued 7,354,000 shares in its public offering on February 9th. The total size of the offering was $139,726,000 based on an initial share price of $19.00.
What is Adagene mAb?
Adagene trades on the NASDAQ under the ticker symbol "ADAG."
Is Adagene a buy or sell company?
Adagene Inc., a clinical stage biopharmaceutical company , engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of various tumors. The company was founded in 2011 and is headquartered in Suzhou, China.
Does Adagene pay dividends?
Adagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Adagene does not currently pay a dividend.
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.
What is data link?
Here's a roundup of top developments in the biotech space over the last 24 hours.
Does market cap include convertible securities?
Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data.nasdaq.com .
